Bottom line
What is SCVAX's expense ratio?
SCVAX's expense ratio is 1.15%, or about $115 a year on every $10,000 invested. That is more expensive than 66% of small-cap funds we track (median 0.99%). This share class also charges a front-end sales load of up to 5.75%, taken from your investment when you buy.
Updated Aug 26, 2026
SCVAX fee table
| Net expense ratio | 1.15% |
|---|---|
| Gross expense ratio | 1.29% |
| Management fee | 0.85% |
| 12b-1 (distribution) fee | 0% |
| Other expenses | 0.44% |
| Fee waiver / reimbursement | -0.14% |
| Max front-end sales load | 5.75% |
| Max deferred sales charge | 0% |
Source: Fund prospectus fee table, filed Aug 26, 2026
What SCVAX costs in dollars
The SEC requires every fund to show what a $10,000 investment would cost, assuming 5% annual returns and that you sell at the end of each period:
| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| SCVAX | $685 | $947 | $1,229 | $2,030 |
Source: Fund prospectus expense example
The long-run cost of fees
On $100,000 growing at 6% a year for 20 years, a 1.15% expense ratio costs roughly $62,900 in lost growth, versus about $54,900 for the median small-cap fund (0.99%).